---
title: "Cancer Biomarkers Market: Growing at a CAGR of 12.4%"
datePublished: Thu Jul 27 2023 10:40:18 GMT+0000 (Coordinated Universal Time)
cuid: clkl0wxk6000m09l2fc0h1x75
slug: cancer-biomarkers-market-growing-at-a-cagr-of-124
ogImage: https://cdn.hashnode.com/res/hashnode/image/upload/v1690454389893/46a9e95f-d5dc-42bc-ab19-af52a83d318d.png
tags: news, business, health-cjaeh844x02vvo3wtj5r2s75q, healthcare

---

## Cancer Biomarkers Market Size, Share & Industry Analysis, By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, and Others), By Biomarker Type (PSA, HER-2, EGFR, KRAS, and Others), By End User (Pharmaceutical & Biotechnology Companies, Diagnostics & Research Laboratories, Hospitals & Specialty Clinics, and Others), and Regional Forecast, 2019-2026  

A cancer biomarker is a biological molecule found in blood, tissue, or other body fluids that is associated with cancer. Cancer biomarkers can be used to diagnose cancer, stage cancer, to monitor treatment response, and to predict the risk of recurrence.

The cancer biomarkers market is growing at a CAGR of 12.4%, driven by the increasing prevalence of cancer, the rising demand for personalized medicine, and the technological advancements in cancer biomarker detection.

**Get More Insights:**Â [https://www.fortunebusinessinsights.com/industry-reports/cancer-biomarkers-market-100630](https://www.fortunebusinessinsights.com/industry-reports/cancer-biomarkers-market-100630)

### **Segmentation**

The cancer biomarkers market is segmented by type, application, and region.

The type segment is further segmented into tumour-associated biomarkers, prognostic biomarkers, and predictive biomarkers. Tumour-associated biomarkers are found in cancer cells or in the blood or tissue of cancer patients. Prognostic biomarkers can be used to predict the course of cancer and the likelihood of recurrence. Predictive biomarkers can be used to predict whether a cancer patient will respond to a particular treatment.

The application segment is further segmented into diagnosis, prognosis, and treatment monitoring. Diagnosis is the largest segment, and it is driven by the increasing demand for early detection of cancer. Prognosis is the second largest segment, and it is driven by the increasing demand for personalized medicine. Treatment monitoring is the smallest segment, and it is driven by the increasing demand for personalized medicine and the need to monitor the effectiveness of cancer treatments.

The region segment is further segmented into North America, Europe, Asia-Pacific, and Latin America. North America is the largest market for cancer biomarkers, due to the high prevalence of cancer and the early adoption of new technologies.

### **Key Players**

The key players in the cancer biomarkers market include Agilent Technologies, Bio-Rad Laboratories, Danaher Corporation, F. Hoffmann-La Roche, QIAGEN, Thermo Fisher Scientific, and Illumina. These companies are investing in research and development to develop new and innovative cancer biomarker detection technologies.

### **Trends**

The cancer biomarkers market is expected to continue to grow in the coming years, driven by the following trends:

* Increasing prevalence of cancer: The global prevalence of cancer is increasing, and this is driving the demand for cancer biomarkers.
    
* Rising demand for personalized medicine: Personalized medicine is a type of medicine that is tailored to the individual patient. Cancer biomarkers can be used to personalize cancer treatment, and this is driving the demand for cancer biomarkers.
    
* Technological advancements: There have been significant technological advancements in cancer biomarker detection in recent years. These advancements have made cancer biomarker detection more accurate and efficient.
    

### **Conclusion**

The cancer biomarkers market is a growing market, and it is expected to continue to grow in the coming years. The market is being driven by the increasing prevalence of cancer, the rising demand for personalized medicine, and technological advancements in cancer biomarker detection.